The 2026 FTSE Playbook for Thai Healthcare

FTSE Russell calibrates its climate bands to each sector's exposure, and healthcare providers sit in the low-to-medium tier: they aren't steelmakers or utilities. But 'low exposure' is not 'low effort.' Hospitals run continuously — theatres, imaging, cold chain, ventilation and infection-control air handling never switch off — so energy intensity per bed and per square metre runs well above a normal commercial building. Layered on top are Scope 1 emissions most other sectors never face: potent halogenated anaesthetic gases such as desflurane and sevoflurane, and propellant-based metered-dose inhalers, each carrying global-warming potentials hundreds to thousands of times that of CO₂.

Yet the bulk of a hospital group's footprint isn't on its own balance sheet at all. Around seven-tenths of health-sector emissions are Scope 3 — pharmaceuticals and chemicals, medical devices and single-use consumables, logistics and outsourced services. A hospital that decarbonises its buildings but ignores procurement has addressed the minority of its footprint. Critically, FTSE doesn't treat healthcare as an environmental story alone: the Social pillar carries unusually high weight here. Patient safety, quality of care, access and affordability, workforce health, and the protection of sensitive patient data are all material, scored themes — and they're where a Thai provider can differentiate fastest.

On the environmental side, expect scrutiny of energy intensity (per bed and per m²), renewable-electricity share and on-site generation, and — distinctively for this sector — anaesthetic-gas and inhaler emissions, which can represent a meaningful slice of a facility's Scope 1 total. Clinical and hazardous-waste management (segregation, treatment, incineration and its emissions), water use in dialysis, sterilisation and laboratories, and above all Scope 3 procurement of pharmaceuticals and medical products round out the climate assessment. Disclosure quality and a credible, ideally SBTi-validated, reduction target lift the score; silence on Scope 3 caps it.

The Social and Governance pillars are where healthcare's rating is often won or lost. FTSE looks for hard patient-safety and care-quality metrics (infection rates, accreditation such as JCI/HA, adverse-event reporting), workforce health and safety, human capital, and access and affordability of care. Data privacy and cybersecurity are explicitly material: under Thailand's PDPA, patient health data is 'sensitive personal data,' demanding a Data Protection Officer, breach notification within 72 hours, and demonstrable technical controls. Governance — board independence, anti-bribery in procurement and referrals, and tax and risk oversight — sits underneath all of it. The methodology draws only on public disclosure, so an unreported control scores as an absent one.